Engineered immune cells take aim at Hard-to-Treat leukemia

This study tests a new treatment for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to recognize and attack cancer cells carrying a protein called PRAME. Participants will receive chemotherapy to prepare their body, followed by the NK cells, to see if this approach is safe and can help control the disease.